Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Receptos Inc announces pricing of underwritten public offering of common stock


Wednesday, 8 Jan 2014 09:42pm EST 

Receptos Inc:Says the pricing of an underwritten public offering of 3,320,000 shares of its common stock at a price to the public of $30.75 per share.Says the gross proceeds to Receptos from this offering are expected to be about $102.1 mln, before deducting underwriting discounts and commissions and other estimated offering expenses.Says all of the shares in the offering are to be sold by Receptos.Says in addition, Receptos has granted the underwriters a 30-day option to purchase up to an aggregate of 498,000 additional shares of common stock.Says the offering is expected to close on or about Jan. 14.Says it intends to use the net proceeds received from this offering to fund continued development of its product candidate RPC1063 in ongoing clinical trials for relapsing multiple sclerosis and ulcerative colitis.development of its in-licensed product candidate RPC4046 in a clinical trial for eosinophilic esophagitis.other ongoing preclinical and research programs and for general corporate purposes including working capital.Says Credit Suisse Securities (USA) LLC, Leerink Partners LLC and BMO Capital Markets are acting as joint book-running managers for the offering.Sasy Wedbush PacGrow Life Sciences is acting as a co-manager. 

Company Quote

51.31
0.11 +0.21%
29 Aug 2014